Soluble Corn Fiber Consumption Effects Executive Functions and Gut Microbiota in Middle to Older Age Adults: A Randomized Controlled Crossover Trial

*David A. Alvarado[1,4], *Tori A. Holthaus[1], Shelby Martell[2], Nicole L. Southey[1], Marco Atallah[4], Rhea Sarma[3], David Revilla[4], Marina Brown[4], Twinkle Mehta[3], Naiman A. Khan[1,2,3,5], Hannah D. Holscher[1,4]

[1]Division of Nutritional Sciences, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
[2]Neuroscience Program, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
[3]Health and Kinesiology, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
[4]Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA
[5]Beckman Institute of Advanced Science and Technology, Urbana-Champaign, Urbana, IL 61801, USA

*Shared first-authorship

Sources of Support: This work was supported by Tate & Lyle Ingredients Americas LLC and the USDA NIFA, Hatch Project (1026591, to HDH).

Clinical Trial Registry: NCT05066425

Corresponding Author: Hannah D. Holscher, 1201 West Gregory Drive Urbana, IL 61801, (217) 300-2512, hholsche@illinois.edu

Data described in the manuscript, code book, and analytic code will be made available upon request.

Abbreviations: Soluble corn fiber (SCF, PROMITOR® Soluble Fibre™), Maltodextrin (CON, control), *Parabacteroides distasonis* (*Pd*), Short-chain Fatty-acids (SCFA), Event-related potential (ERP), Reaction Time (RT), Positive and Negative Affect Schedule (PANAS), Perceived Stress Score (PSS), carbohydrate-active (CA), Profile of Moods (POMS), Cambridge Neuropsychological Test Automated Battery (CANTAB), SE (Standard Error), SEM (Standard Error of the Mean), Std (Standardized)

Abstract

Background: Adequate dietary fiber may improve cognitive function through gut microbiota-

mediated mechanisms, but human trials remain limited.

Objectives: This study evaluated the effects of soluble corn fiber (SCF) on cognition,

gastrointestinal microbiota composition, and fermentation end-products, with pre-defined aims to

investigate gastrointestinal microbiota-dependent mechanisms by which SCF consumption may

underpin cognitive performance.

Methods: This randomized, double-blind, crossover trial included 42 healthy adults (45-75 yr)

asked to consume maltodextrin (CON, 22 g/d) or SCF (22g/d; 18g/d fiber) for 4 weeks, separated

by a 4-week washout in a counterbalanced order. Outcome assessments included cognitive

control via the flanker task (with event-related potentials), Cambridge Neuropsychological Test

Automated Battery (CANTAB), Profile of Moods Survey (POMS), and relational memory tasks;

fecal microbiota via 16S rRNA and shotgun sequencing, targeted metabolomics via GC-MS; and

self-reported subjective GI tolerance symptoms via daily questionnaires. *In vitro* and genomic

analyses characterized microbial species and genes facilitating SCF fermentation.

Results: SCF consumption improved reaction times (RT) for congruent (P=0.03) and

incongruent (P=0.002) task conditions of the flanker task compared to CON. Faster congruent

RT was correlated with greater fecal concentrations of acetate (ρ= -0.33, P=0.048) and

propionate (ρ= -0.36, P=0.03). *Parabacteroides* abundance was enriched with SCF (FDR

P<0.001) and correlated with fecal acetate ($\rho = 0.34$, P=0.04) concentrations. Mediation analyses

revealed no significant indirect effects; however, moderation analyses showed that the

abundance of *Parabacteroides* moderated the effect of treatment on RT (P=0.03). Fecal

metagenomic profiles from microbial responder identified *P. distasonis* (*Pd*) as the primary

species enriched from SCF consumption. *In vitro* culturing of *Pd* exhibited diauxic growth on

SCF, characterized by an initial non-fiber sugar utilization phase (0-4 hrs), a lag phase (4-6 hrs),

and a subsequent fiber fermentation phase (6-10 hrs), confirming its direct utilization of SCF.

The predicted metagenome suggests SCF-enriched KEGG carbohydrate metabolism pathways

(FDR $P < 0.05$), including carbohydrate-active (CA) KOs (FDR $P < 0.05$).

Conclusion: SCF consumption improved attentional inhibition and increased *Parabacteroides*

abundance. Correlation analyses indicated higher *Parabacteroides* abundance were associated

with increased fecal acetate, and fecal acetate was correlated with quicker congruent RTs. While

no mediation was observed, *Parabacteroides* significantly moderated cognitive benefits,

supporting the relevance of microbiota composition in shaping dietary fiber responsiveness in

older adults.

Keywords: Reaction time, Attentional inhibition, Parabacteroides, gut-brain axis, cognitive

control

Introduction

Converging evidence increasingly demonstrates the benefits of certain nutrients and

overall diet quality to cognitive health and brain function[1–3]. Preclinical models have shown that

high-fiber diets can improve cognitive function[4,5], yet human intervention studies remain scarce[6–

8]. While much is known about the influence of dietary fiber on the gut microbiota, fewer studies

have examined its impact on human cognitive function[9–11], and fewer still have explored the gut-

microbiota-brain axis in rigorously controlled trials. These gaps highlight the need for clinical

research evaluating whether fermentable fibers can influence cognition through gut microbiota-

mediated mechanisms.

Resistant maltodextrins, such as soluble corn fiber (SCF), have physiological health

benefits, including glycemic control, calcium and bone retention, and gastrointestinal health[9–11].

SCF is a non-viscous, water-soluble fiber with an average degree of polymerization (DP)

between 10-12[12]. Due to its structural complexity, < 30% of SCF is digested in the small

intestine, allowing it to reach the colon to be fermented by resident microbes[13,14]. SCF promotes

the growth of commensal taxa, such as *Bifidobacterium*, *Lactobacillus,* and *Parabacteroides*[15,16],

and increases short-chain fatty acid (SCFA) production across age groups[17]. These microbiota

and metabolite shifts are potential pathways through which SCF could influence cognitive

function, particularly via gut-brain signaling[18,21–24].

Cognitive functioning is supported by several executive processes, including inhibitory

control, which enables individuals to suppress automatic responses in favor of goal-relevant

behavior[18]. This form of top-down regulation is fundamental to attentional focus, working

memory, and behavioral flexibility and is often assessed through tasks that require resolving

conflicting information or suppressing irrelevant stimuli[18]. In addition to behavioral performance

measures such as accuracy (ACC) and reaction time (RT), neural markers of cognitive control

can be captured using event-related potentials (ERP) derived from electroencephalographic

(EEG) activity[19,20]. Given the growing evidence that microbial metabolites can influence brain

signaling and cognitive performance[21–26], examining both behavioral and neuroelectrical markers

provides a comprehensive evaluation of SCF's potential cognitive effects[26,27,33].

This study aimed to assess the effects of SCF consumption on behavioral measures of

cognitive functions among middle- and older-aged adults. For our primary aim, we hypothesized

that daily SCF consumption over four weeks would improve cognitive control and hippocampal-

dependent relational memory compared to placebo control. Furthermore, we aimed to examine

the impact of SCF consumption on neuroelectric indices of inhibitory control, hypothesizing that

SCF would improve neural efficiency. Secondary aims include assessing the effects of SCF

consumption on fecal microbiota and fermentation end-products. Finally, pre-determined tertiary

aims were to investigate whether cognitive improvements are mediated or moderated by

microbial and microbial metabolite changes.

Methods

Study design and intervention

This study used a double-blind, randomized, placebo-controlled, repeated measures

crossover design with two conditions (2x2 Latin square design). The intervention periods lasted

four weeks each, with a minimum two-week washout period between the conditions. Participants

were asked to consume 22 g/day of SCF (PROMITOR® Soluble Fibre™) containing 18g of SCF

or 22 g/day of maltodextrin (CON) during the respective intervention conditions. The two

supplements were identical in taste and appearance and were provided by Tate & Lyle in pre-

measured sachets of powder marked with a numerical identifier only to maintain the blindness of

the researchers and participants. All participants and research staff were blinded until data

analyses were completed. Since previous research has not directly examined the effects of SCF

consumption on cognitive function, we relied on a conservative approach, estimating a small

effect size. Based on an *a priori* power calculation (G-Power 3.1.9.2)[27] using an α of 0.05, β of

0.80, and a small effect size ($r = 0.20$), we determined that a total sample size of 36 participants

would be sufficient to conduct these analyses.

Participants were given 35 powder sachets per intervention period and were instructed to

mix one sachet of the powdered supplement into a liquid of their choice once daily for four

weeks. Participants were given a paper-based compliance log to track daily supplement intake

during each intervention period and were asked to return the log and any remaining sachets at the

end of each period for compliance tracking. Participants completed two in-person baseline

testing appointments before supplement deployment. Demographic and medical history were

collected via survey, including age, sex, approximate annual income, highest education level,

race, and ethnicity. Anthropometric measures and a cognitive battery were administered before

and after each intervention period. Participants performed cognitive testing during the first and

second baseline visits to minimize practice effects, and the cognitive tasks were presented in a

counterbalanced order at each visit using a Latin square design to avoid fatigue and order effects.

The study visits (**Supplemental Figure 1**) were conducted at the University of Illinois.

Participants criteria

Adults aged 45-75 years were recruited from the East Central Illinois area using popular

email newsletters, social media postings, community event displays via the postal service, and

flyers posted on public transport. Participants were excluded if they reported a previous

physician diagnosis of gastrointestinal or metabolic disease, including inflammatory bowel

disease and diabetes, had a prior diagnosis of any neurological disease, including dementia,

Parkinson's disease, multiple sclerosis, brain tumors, or autism, had colorblindness or vision not

corrected to 20/20, had antibiotic use within the last month, tobacco use, food allergies, and if

they were pregnant or lactating.

The study was registered on ClinicalTrials.gov (clinicaltrials.gov/study/NCT05066425),

approved by the University of Illinois Institutional Review Board, and conducted following the

principles of the Declaration of Helsinki. Participants were informed of all procedures, and their

written informed consent to the study procedures was obtained before data collection. Following

informed consent, participants were screened in person and excluded if their BMI was <18.5 or

>34.9 kg/m^2, if they had cognitive impairment as evidenced by a score of less than 24 on the

Mini-Mental State Examination, and if their intake of dietary fiber was > 70% of the Daily

Recommended Intake for fiber (≥18 g fiber per day for women and ≥27 g fiber per day for men)

according to the results of their completed Dietary History Questionnaire version 3 (DHQ3) food

frequency questionnaire. Eligible participants were then invited to complete further testing and

were asked to refrain from taking other probiotic or nutrition supplements and keep their dietary

intake and physical activity consistent for the duration of the study.

If participants were recruited and passed screening tests, they were randomized to start in

a counterbalanced order in either the SCF or CON group (**Table 1**) and assigned a study id (e.g.-

SC101) inputted onto REDCap by a trained member of the team. The Study Coordinator

generated the sequence of interventions assigned using a simple randomization approach (coin

toss) for each enrolled participant. Participants were given sachets labeled as 030 or 789, CON

and SCF, respectively, to ensure double blinding throughout the study until completion.

Weight Status

For each visit, the participant's height and weight were measured in light clothing and

without shoes using a SECA stadiometer (model 240; SECA, Hamburg, Germany) and Tanita

WB-300 Plus digital scale (Tanita, Tokyo, Japan). Height and weight were taken in triplicate,

and the average was used to calculate BMI using the formula weight [kg]/height [m^2].

Flanker task

Attentional inhibition was assessed using a modified Eriksen flanker task as previously

described [28]. Briefly, participants were asked to respond (Current Designs, Philadelphia, PA,

USA) quickly and accurately to the directionality of a central stimulus (3-cm tall white arrow)

presented with two flanking stimuli on each side (83s stimulus presentation and 100ms response

window, and jittered intertrial intervals of 1100, 1200, and 1500 ms). During congruent trials,

the flanking arrows faced the same direction as the central arrow (i.e., <<<<<, >>>>>). During

incongruent trials, the flanking arrows face the opposite direction of the central stimuli (i.e.,

>><>, <<><<), requiring greater upregulation of attentional inhibition. The task began with 40

practice trials followed by two blocks of 200 randomized experimental trials. Behavioral

measures of interest included accuracy (ACC) and reaction time (RT) for correct responses

during congruent and incongruent trials. The interference effect (flanker effect) for ACC was

also derived by subtracting the ACC on congruent flanker trial types from ACC on incongruent

trial types. The interference effect for RT was calculated by subtracting incongruent from

congruent RT. These outcomes index the ability of participants to maintain task performance

between the two trial types.

ERP assessment

EEG activity was recorded simultaneously during the flanker task via a Neuro-scan Quik-

cap with 64 passive, wet, sintered Ag/AgCl scalp electrodes arranged in the international 10–10

system with electrodes placed near the outside each eye and above and below the left eye [29]. A

midline sensor placed between CZ and CPZ served as a reference, and AFZ served as the

ground. Continuous EEG data was digitized using a Neuroscan SynampsRT amplifier at a

sampling rate of 500 Hz, amplified 500 times to an online low-pass 70-Hz filter with a direct

current and a 60-Hz notch filter. Electrode impedance values were maintained at ≤20 kohms.

Signal processing and analyses were performed in MATLAB (MathWorks, Natick, MA,

version 2021b) using the EEGLab and ERPlab toolbox plug-ins [30,31]. Continuous data were re-

referenced to the average of two mastoid electrodes. A trained research team member visually

inspected all channels for excessive noise during pre-processing. Channels with excessive noise

were interpolated with an average of the adjacent electrodes. Data were submitted to a 0.1 Hz

high-pass Butterworth filter before eye-blink artifacts were rejected using independent

component analysis (ICA). ICA and vertical eye sensor channel correlations greater than 0.35

were considered eye-blinks. A time window of −200 to 1200 ms around stimulus presentation

was used for creating stimulus-locked epochs with a baseline correction of −200 ms to stimulus

onset. A 30-Hz low-pass filter was used. Artifacts were detected and rejected if a moving

window peak-to-peak amplitude exceeded 100 μV, using a 100 ms window width and step. Only

correct trials from individuals who reported >80% of artifact-free trials in all Flanker task trials

were included in analyses (>20% artifacts: N=3 CON, N=4 SCF), consistent with previous

literature [32,33].

Electrodes of interest were chosen based on a collapsed localizer technique[34]. Evidence

for selection was observed from maximal voltage localization of combined baseline and post-

testing trials collapsed across condition and trial type. Post-hoc topographic average plots were

constructed using a stylized topographic map plugin for EEGLAB/ERPLAB[35]. From these plots,

the P3 component was defined as a region of interest comprised of C1, CZ, C2, CPZ, CP1, and

CP2 with localized peak and corresponding latency between 300 and 600 ms post-stimulus onset.

Relational memory assessment

A computerized spatial reconstruction task, iPosition, was used to assess hippocampal-

dependent relational memory using Presentation Software (Neurobehavioral Systems, Berkeley,

CA) as previously described [36]. Participants viewed six abstract shapes on the computer screen in

a randomized array for 6 seconds, which were then masked by small black squares for 18

seconds and could be viewed individually by clicking on each square. The boxes then

disappeared, and the stimuli reappeared at the top of the screen after a 2-second lag. Participants

were asked to reconstruct the randomized array they previously studied for a total of 20 trials.

Two error metrics were used to assess performance: misplacement (original misplacement),

calculated as the average measure of distance between the actual and reconstructed stimuli

locations, and object-location binding (accurate single item placement), the number of times the

participant correctly placed a stimulus within a pre-defined radius.

Neuropsychological assessment

The Cambridge Neuropsychological Test Automated Battery (CANTAB, Cambridge

Cognition Ltd) was used to test cognitive performance across multiple domains presented on a

tablet with a touchscreen. The battery included the Intra-Extra Dimensional Set Shift (IED), Stop

Signal Task (SST), Rapid Visual Information Processing (RVP), and Spatial Working Memory

(SWM). The IED is a test of executive function and assesses rule acquisition and reversal,

attentional set formation, maintenance, and shifting. The RVP task assesses sustained attention,

The SST measures response inhibition. The SWM task assesses spatial working memory.

Mood States and Psychological assessment

Mood and psychological functioning were assessed using four validated self-report

instruments: the Profile of Mood States (POMS), the Positive and Negative Affect Schedule

(PANAS), and the Perceived Stress Scale (PSS). The POMS is a 65-item questionnaire that

evaluates transient mood states across six subscales (Tension-Anxiety, Depression-Dejection,

Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment), with

participants rating how they felt "right now" on a 5-point Likert scale ranging from 0 ("not at

all") to 4 ("extremely")[37]. The PANAS consists of 20 items, evenly divided into positive and

negative affect subscales, where participants indicate to what extent they generally experience

each emotion using a 5-point scale from 1 ("very slightly or not at all") to 5 ("extremely")[38]. The

PSS includes 10 items designed to assess perceived stress over the past month, with responses on

a 5-point scale ranging from 0 ("never") to 4 ("very often") [39]. Physical activity was assessed

using the Godin-Shephard Leisure-Time Exercise Questionnaire, measuring the frequency of

strenuous, moderate, and light physical activities performed for more than 15 minutes during a

typical week. A total leisure activity score was calculated using the weighted formula: (9 x

strenuous) + (5 x moderate) + (3 x light).

Fecal collection and processing

During the five days before starting each intervention condition and the last five days

during their last week (days 25-30) of each treatment and washout period, participants were

asked to provide two fecal samples for each timepoint (2 x PRE and 2 x POST for both SCF and

CON). Participants were instructed to provide fecal samples within 15 minutes of defecation

using provided materials, including Commode Specimen Collection Systems (Sage Products),

ice packs, and coolers. Samples were homogenized upon arrival in the laboratory, aliquoted into

cryovials for sequencing, flash-frozen in liquid nitrogen, and stored at -80°C. Fecal samples were

also aliquoted into 15mL test tubes for phenol/indole measurements, pre-weighed aluminum tins

to calculate the dry matter basis (DMB), and acidified with 2N-HCl (10% wt:vol) for SCFAs

(acetate, propionate, butyrate), BFCAs (valerate, isovalerate, isobutyrate), and ammonia; these

aliquots were all frozen at -20°C until analysis. A fecal pH measurement (Denver Instrument)

was also recorded for each sample.

Fecal DNA isolation and 16S amplicon analyses

Fecal microbial DNA was extracted utilizing the Power-Lyzer PowerSoil DNA Isolation

Kit (QIAGEN). DNA quality was assessed using 1% agarose gel, and concentrations were

measured using a Qbit 3.0 Fluorometer (ThermoFisher Scientific). Extracted DNA from the two

fecal samples collected at each time point were pooled in equimolar amounts and sequenced at

the University of Illinois W. M Keck Center for Biotechnology. 16S amplicon sequencing

utilized V4 primers (forward (F): 5'-GTGYCAGMGCCGCGGTAA, reverse (R): 5'-

GGACTACNVGGGTWTCTAAT) with a NovaSeq 6000 SP with 2x250nt to produced ~1

billion reads. High-quality (quality score > 25) sequence data were filtered using DADA2[40]

integrated within QIIME2 software (v2023.7)[41]. Sequences were denoised and resolved into

amplicon sequence variants (ASVs) using the SILVA 138-99 (515F/806R) naïve Bayes

reference classifier [40,42]. After quality filtering, samples were rarefied to a depth of 350,000

sequences, corresponding to the minimum sampling depth across all samples. At this sequencing

depth, rarefaction curves plateaued across all samples, indicating sufficient coverage of amplicon

ASVs (**Supplemental Figure 2**). Rarefaction was performed using the vegan package (v2.6.8)[43]

with a fixed pseudo-random number generator (set.seed = 8) in RStudio (v2024.12.0). No library

was driven to zero counts. Rarefaction removed 1,521 of the original 11,894 ASVs (13%): 909

were singletons, and 612 had zero counts in the unrarefied dataset. A total of 10,373 ASVs

(87%) were retained for analyses.

Alpha and beta diversity measures were performed with the R vegan and phyloseq

(v1.48.0)[44] package. Alpha diversity was calculated using phyloseq for richness and Shannon

indices. Then, a linear mixed effect model with treatment-by-time interaction and the participant

was utilized as the random intercept. Bray-Curtis dissimilarities (distance(method="bray")) and

weighted UniFrac distances (distance(method="wunifrac")) were also calculated using phyloseq.

We then performed PERMANOVA via adonis2() (vegan) with 5,000 permutations to assess the

effects of treatment, time, and their interaction on community composition, and tested for

homogeneity of group dispersions with betadisper() and permutest(). For visualization the

function ordinate(method="PCoA") and plot_ordination()

Differential abundance was conducted on normalized rarefied feature table using

phylotype_analysis. Relative abundance was used for visualization and table summaries (sweep,

MARGIN=1, rowSums). Before modeling differential abundance, the count data were filtered to

improve model stability and reduce noise. First, genera with a total count of zero across all

samples were removed. Next, a minimum total read count threshold was applied, retaining only

genera with at least 0.01% reads across all samples. A prevalence filter was also used, retaining

taxa present (nonzero counts) in at least 40% of samples. The generalized linear mixed effect

modeling included only taxa meeting the filtering criteria.

Predictive metagenomics analyses were conducted using PICRUSt2 (v2.5.3)[45] to assess

the functional potential for each sample from the complete cohort (picrust2_pipeline.py with

default parameters)[45,46]. The output includes the ko mapping (ko_info), unstratified KO, and EC-

predicted metagenome files, which were used for broad function and pathway differential

abundance analyses with the R-package ggpicrust2 (v.1.7.3)[47] using LinDA method. The KO-

predicted metagenome (KO pred metagenome contrib) file was used for a granular analysis for

all KOs using the R-package MaAsLin2 (v1.18.0)[47,48]. The parameters set in MaAsLin2 included

a fixed effect of the treatment, a random effect of participant, a 50% minimum prevalence

(default 10%), and the default P-adjustment (FDR). This was between the baseline, end-to-end,

and baseline compared to the respective end-point. We selected carbohydrate metabolism-related

pathways and KEGG orthologs to limit the KOs investigated. The mapping files were imported

using R-package KEGGREST (v112.1) to create a filtering vector which included:

Glycolysis/Gluconeogenesis (map00010), Pentose phosphate pathway (map00030), Fructose and

mannose metabolism (map00500), Pyruvate metabolism (map00620), Butanoate metabolism

(map00650), and additional KOs including alpha-amylase (K01176), alpha-amylase glycosidase

(K01223), beta-glucosidase (K01210), Glucan 1,4-alpha-glucosidase (K01190), alpha-

glucosidase (K01187), alpha glucosidase GH183 and GH97 (K012348). The predicted KO

metagenome stratified file provided the normalized taxon contribution

(norm_taxon_function_contrib) for each KO, allowing the genera-level visualization of

contribution for the selected associated KOs to compare between treatments.

Microbial Metabolites

Fecal dry matter was measured according to the methods of the Association of Official

Analytical Chemists, 1984[49]. Ammonia concentrations were determined using methods outlined

by Chaney and Marbach[50]. Fecal sample aliquots for SCFA and BCFA concentrations were

weighed, acidified with 2N hydrochloric acid, and stored at -20°C until analysis. Before analysis,

samples were thawed at room temperature for 15 minutes and centrifuged at 13,000g for 10 min.

Gas chromatography mass spectroscopy (GC-MS) was used for quantification, normalized by

dry matter weight[51]. Phenol and indole concentrations were quantified, according to Flickiet al.

et al.[52]. Fecal metabolite concentrations are reported on a dry matter basis.

Digestive health

Gastrointestinal symptoms, bowel function, and stool characteristics were measured

using 7-day self-reported records, questionnaires, and stool processing in the laboratory before

and after each intervention period[53]. The 7-day self-reported gastrointestinal symptom records

included subjective ratings (1 [absent], 2 [mild], 3 [moderate], and 4 [severe]) for burping,

cramping/pain, distension/bloating, flatulence/gas, nausea, reflux (heartburn), and rumblings.

Participants also recorded their bowel movement consistency (1 [separate hard lumps], 2

[sausage-shaped but lumpy], 3 [sausage-like but with cracks on the surface], 4 [sausage-like,

smooth, and soft], 5 [soft blobs with clear cut edges], 6 [fluffy pieces, mushy], and 7 [entirely

liquid]) and ease of passage (1 [very easy], 2 [easy], 3 [neither easy nor difficult], 4 [difficult], 5

[very difficult]). In the laboratory, upon collection of each fresh fecal sample, pH was measured

using a pH meter (Denver Instrument)[53]. A trained research team member recorded their

assessment of the Bristol stool consistency of the fecal sample.

In vitro culturing of Parabacteroides distasonis

Utilizing an adapted protocol from Garcia-Bayona et al[54]. *Parabacteroides distasonis*

(*Pd*) -- 31_2 (deposited as *Porphyromonas* sp., Strain 31_2, HM-169) was obtained through

Biodefense and Emerging Infections Research Resources Repository (BEI Resources), National

Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH) as part

of the Human Microbiome Project in anaerobic brain heart infusion (BHI) and chopped meat

media. To test the effects of different carbohydrate sources, an M9 minimal medium was

prepared and supplemented with essential nutrients, including 50 mg/L L-cysteine, 5 mg/L

hemin, 2.5 µg/L vitamin K1, 2 mg/L FeSO4·7H2O, and 5 µg/L vitamin B12. The carbohydrate

sources added to the M9 medium were either 0.25% (wt/vol) glucose (M9-Glu), 0.25% CON

(M9-CON), or 0.4% (wt/vol) SCF (M9-SCF). As a positive control, the BHI medium was used

to verify the *P. distasonis* strain viability. The M9 medium without any added carbohydrates

served as a negative control to confirm that no other medium component contributed to bacterial

growth. Additionally, each medium had a blank control containing no *Pd* inoculum to ensure no

contamination and allowed any background noise from the media to be subtracted.

Hemin stock solution was prepared at a final concentration of 5 mg/L by dissolving 10

mg of powdered hemin in 10 mL of 0.05 M NaOH. The solution was sterilized using a 0.22 μm

filter and stored at 4°C. Vitamin K1 stock solution was prepared to a final concentration of 2.5

μg/L, 2.5 mg of powdered vitamin K1 was dissolved in 0.5 mL of 100% ethanol, followed by

dilution to 10 mL with sterile distilled water. The solution was sterilized via filtration and stored

at 4°C. L-cysteine hydrochloride solution was prepared to a concentration of 50 mg/L by

dissolving 100 mg of L-cysteine in 10 mL of sterile molecular-grade water. The solution was

filter sterilized and stored at 4°C. To ensure sterility, all solutions were prepared within a

chemical fume hood and biosafety cabinet. *Pd* was cultured overnight in BHI broth. A 20 μL

aliquot of the overnight culture was inoculated into 180 μL of M9 medium, achieving a 1:10

dilution and a starting OD_{600} at approximately 0.1 absorbance.

Three biological replicates consisting of three technical replicates for each per treatment

were plated on a 10 x 10 honeycomb plate. The Bioscreen-C was programmed to measure the

OD_{600} at regular intervals (30 min), the lowest interval setting allowed using a 600 nm brown

filter while maintaining a temperature of 37°C and shaking for 5 seconds before and after each

reading. OD_{600} measurements were collected for 25.5 hrs using BioScreen-C for each biological

and technical replicate for each substrate and the triple blanks (no *Pd* inoculate) for each

technical replicate (**Supplemental Figure 3**). The blank samples would confirm no growth

without any inoculation in the media with and without a substrate. Since all cultures reached the

stationary phase by 14 hrs across all the carbohydrates, statistical analyses were restricted to the

first 14 hrs. Optical density readings were adjusted by subtracting blank values to remove

background media noise for downstream analyses.

$$\text{Adjusted OD} = \text{OD}_{\text{Sample}} - \text{OD}_{\text{Blank}}$$

Growth rates were calculated at 2-hr intervals throughout the first 14 hrs to capture the

dynamic changes in bacterial growth across different carbohydrate sources. For each biological

replicate, the specific growth rate (μ) was calculated as the slope between consecutive $\ln(OD_{600})$

values over 2-hour intervals, where time (hrs) served as the independent variable and $\ln(OD_{600})$

as the dependent variable.

$$\text{Growth rate } (\mu) = \frac{\ln(OD_t) - \ln(OD_{t-2})}{2}$$

Genomic analyses of a subsample of responders and non-responders

Shotgun metagenomics utilized a subsample population ($N = 6$) of responders (n=3) and

non-responders (n=3), including PRE and POST fecal samples from the SCF condition.

Responder status was determined based on a participant's delta enrichment of *Parabacteroides*

following the SCF intervention (**Supplemental Figure 4**). Delta values were calculated using the

relative abundance values for each participant. A positive delta value was categorized as

responders, while a negative or null delta was categorized as non-responders. The samples

selected for metagenomic sequencing were from participants with the three lowest and three

highest delta values (responders).

The whole metagenome for the 12 fecal DNA samples (baseline and end samples from

the SCF condition for three responders and three non-responders) was sequenced at the W. M.

Keck Center for Biotechnology at the University of Illinois Urbana-Champaign. Libraries were

pooled, quantified by qPCR, and sequenced on one half of a 10B lane for 151 cycles from both

ends of the fragments using a NovaSeq X Plus with V1.0 sequencing kits. FastQ files were

generated and demultiplexed with the bcl2fastq v2.20 Conversion Software (Illumina). Adapters

(CTGTCTCTTATACACATCT) were trimmed from the 3'-end of the reads. The quality scores

in the FastQ files used an ASCII offset of 33, known as Sanger scores. Shotgun metagenomic

data processing and bioinformatics analyses were performed using the Carl R. Woese Institute

for Genomic Biology (IGB) Biocluster at the University of Illinois at Urbana-Champaign.

Pre-processing was performed using KneadData (v0.12.0) for quality control and host

contaminant removal on paired-end FASTQ files, utilizing 25 processing threads for optimized

parallel processing. Trimmomatic (v0.39) was employed for adapter removal and quality

trimming, while Tandem Repeat Finder (TRF) was used to identify and remove repetitive

sequences. Quality control reports were generated at multiple stages using FastQC (v0.11.9).

Host DNA sequences were filtered against the KneadData database (20230405 release). The

cleaned, high-quality paired-end reads were concatenated per sample using the --cat-final-output

flag for downstream processing. Taxonomic profiling was conducted using MetaPhlAn[55]

(v4.0.6), which employed Bowtie2 (v2.5.0) to align reads against the ChocoPhlAnSGB_202212

reference database. The kneaddata-filtered FASTQ files were analyzed using the

rel_ab_w_read_stats mode, normalizing taxonomic abundances while preserving read count

information using 25 processing threads. Following taxonomic profiling, individual sample

profiles were merged to generate study-wide abundance tables. The merge_metaphlan_tables.py

script [55] aggregates relative abundance profiles across all samples. To develop an absolute

abundance table, we used a modified script (merge_metaphlan_tables_abs.py), which included a

single-line modification to allow the merging of absolute abundances instead of relative values.

The script was obtained from BioBakery (https://github.com/timyerg/Metaphlan-absolute-

abundance-merger/) and requires that MetaPhlAn be run with -t rel_ab_w_read_stats to capture

read count information alongside relative abundances as described earlier. Functional profiling of

microbial communities was conducted using HUMAnN (v3.7)[56] to characterize gene families

and metabolic pathways. HUMAnN3 was applied to the kneaddata-filtered FASTQ files,

utilizing taxonomic profiles generated by MetaPhlAn to improve species-resolved functional

annotation. The analysis incorporated the ChocoPhlAn nucleotide database (v201901b) and the

UniRef90 protein database (November 2024) to stratify gene functions at the species level.

Following functional profiling, UniRef90 gene family identifiers were mapped to their respective

protein descriptions using the HUMAnN "human_rename_table" function for interpretable

annotations for downstream analyses.

For gene family analyses, we conducted log fold comparisons between responders and

non-responders $\log_2$[(delta R/delta NR)]. All gene families with a log fold change >2 were

selected, yielding over 2000 gene family clusters. To focus on carbohydrate-active gene families,

a targeted filtering approach was applied using key terms associated with carbohydrate

metabolism, including "Alpha-amylase," "Glycoside hydrolase," "Glycosyl hydrolase,"

"acetate," "butyrate," "propionate," "pyruvate," "Glycosyl transferase," "hexokinase,"

"glucokinase," "glucose," and "carbohydrate." This refinement reduced the dataset to 217 gene

families, from which the top 40 with the highest positive log fold change were selected for a

correlation heatmap using z-normalized abundance values.

CAZy was utilized to determine higher resolution of carbohydrate-active enzymes[57,58]

from the metagenomic data in responders and non-responders. Raw sequencing reads were pre-

processed using Trim Galore (v0.6.0) to remove adapter sequences and low-quality bases, and

contaminants were identified using Kraken2 (v2.1.1) with a standard database. Clean reads were

assembled into contigs using MEGAHIT (v1.2.9); assembly quality was assessed by applying a

minimum contig length threshold (≥1000 bp) and examining general assembly statistics provided

by MEGAHIT. Gene prediction and annotation were conducted using Prokka (v1.4), generating

protein sequences and gene annotations. CAZyme annotation was performed using run_dbcan

(v4.0.0)[59], employing three methods: HMMER searched against the dbCAN HMMdb for

CAZyme family-level annotation, DIAMOND searched against CAZy annotated protein

sequences, and HMMER search against the dbCAN-sub HMMdb for substrate prediction. The

outputs included annotated CAZymes, their associated families, predicted CGCs (Carbohydrate-

active Gene Clusters), and substrate assignments based on the dbCAN-sub HMMdb and

validated PUL (Polysaccharide Utilization Loci) datasets. To quantify CAZyme abundances,

clean reads were mapped to coding sequences and contigs using BWA (v0.7.17-r1188), with

sorting performed via Samtools (v1.7) and read counts calculated using Bedtools (v2.27.1).

Abundance metrics such as transcripts per million were computed using dbcan_utils scripts

within the run_dbcan package[59]. The workflow was executed on a Linux computer with 128 GB

RAM, utilizing Anaconda (v23.7.3) for environment management to streamline software

installation and dependency handling.

Statistical analyses

The study's primary outcomes were assessed using a linear mixed effect model for an

end-to-end comparison between conditions with baseline values included as a covariate. For

example, the Flanker task ACC following each intervention (SCF and CON) was analyzed using

linear mixed-effects models, controlling for baseline ACC on the flanker task within each

condition. Data was analyzed in R version 4.4.3. using the packages: "lme4" (v1.1.37),

"glmmTMB "(v1.1.11), "lmerTest" (v3.1.3), "emmeans" (v1.11.0), "Hmisc" (v5.2.3), "rstatix"

(v0.7.20, "coin" (v1.4.3), "vegan" (v2.6.10), "phyloseq" (v1.48.0), "MaAsLin2" (v1.18.0),

"ggpicrust2" (v2.0.0), "interactions" (v1.2.0), and "mediation" (v4.5.0) [45,47,48,60–64]. Data and

residuals were examined for normality using the Shapiro-Wilk statistic, visually inspected using

Q-Q plots, and homogeneity of variances was tested using Levene's test. Linearity between

baseline covariates and response variables was assessed using simple linear models. The α-level

was set at 0.05 (two-tailed). For all regression models, the standardized beta coefficients (β_{std})

and 95% CI were calculated using the "parameters" (v0.25.0) package in R.

Log transformation was applied to acetate, propionate, and total SCFA, while a square

root transformation was applied to RT Interference, Peak Latency, PANAS, POMS, Godin

valerate, isovalerate, total BCFA, and ammonia to meet assumptions for the linear mixed effect

model. Two Flanker task ACC scores, two ERP mean amplitudes, and one fecal butyrate

concentration were winsorized due to extreme outliers (>3 standard deviations)[65,66]. For

congruent models, if an interaction between congruency and treatment with $P<0.05$, then a *post-*

hoc was conducted between treatment for each congruency with Benjamini-Hochberg *P*-

adjustment (method = "BH").

A linear mixed effect model was applied to microbiota alpha diversity metrics, while beta

diversity was assessed using permutational multivariate analysis of variance (PERMANOVA)

with 5,000 permutations, both using treatment by time as fixed effects and ID for the random

intercept. The 16S microbiota data, as part of the secondary outcomes, were assessed using

generalized linear mixed models fitted with a negative binomial distribution and a log link

function (family = nbinom2(link = "log")) [67–69]. For each taxon, a null model, which included

only a random intercept for participant ID, was compared to a full model that included treatment

by time as fixed effects and a random effect for participant ID. Including baseline abundance as a

covariate caused model instability or singularity issues; therefore, this analysis did not use the

baseline covariate model. Model comparisons were conducted using likelihood ratio tests (LRTs)

assessed with anova() to determine whether the addition of fixed effects (treatment, time, and

their interaction) significantly improved model fit compared to the null model. False discovery

rate (FDR) correction was applied across all genera and phyla using the qvalue() function to

adjust for multiple hypothesis testing. Taxa with significant LRT q-values (FDR $P < 0.05$) were

subjected to *post-hoc* analysis using the least square means (emmeans) to perform pairwise

comparisons between treatments within each time (PRE and POST), *post-hoc P*-values were

further adjusted (method = "BH") to control for multiple comparisons.

The Wilcoxon signed-rank test was applied to gastrointestinal symptoms and CANTAB

data (IBM, Armonk, NY, USA) due to the inability to meet linear model assumptions. Delta

scores (POST minus PRE) stratified by treatment (SCF and CON) were analyzed for these

outcomes to evaluate intervention effects.

Analysis of the in vitro *Pd* growth utilized a linear mixed-effects model to compare

growth rates across different carbohydrate sources (SCF, CON, glucose) at each time point, with

biological replicate (BioRep) included as a random effect to account for repeated measures. Post-

hoc pairwise comparisons were performed using BH adjustment to identify significant

differences between growth rates at each interval [70].

Mediation analyses consisted of two linear regression steps: (1) a mediator model

predicting the mediator from treatment, adjusted for baseline mediator levels, and (2) an outcome

model predicting cognitive response (i.e.- congruent RT) from treatment and the mediator,

adjusted for baseline response of the cognitive measure and baseline mediator levels.

Bootstrapped mediation analyses were performed using the mediate function from the R package

"mediation" (v4.5.0), employing 8000 bootstrap simulations to estimate the average causal

mediation effect (ACME), direct effect (ADE), total effect, and proportion mediated. Sensitivity

analyses were performed using the medsens() function from the mediation package to assess the

robustness of the mediation results to potential violations of the sequential ignorability

assumption, ensuring the measured effects are not biased by unobserved confounding factors.

Moderation analyses were conducted to examine whether fecal microbiota and metabolites

moderated the relationship between treatment and cognitive measures (e.g.- congruent RT).

Separate moderation models were fitted for each moderator (e.g.- *Parabacteroides*). Each model

included the interaction term between treatment (as.factor, reference = CON) and the centered

moderator variable (center = TRUE, scale = FALSE), adjusted for baseline of the response

measure and baseline levels of each respective moderator. Moderator variables were mean-

centered to facilitate interpretation. If an interaction effect was flagged as significant, post-hoc

analysis using the Jonhson-Neyman (JN) method with the function sim_slope() from the R

package "interaction" (v4.4.3) and least square means were employed, verifying the moderation

simple slopes and effects at low (-1 SD), mean, and high (+1 SD) moderator levels.

Results

520   *Participant characteristics*

521   The study consort (**Figure 1**) demonstrates the study recruitment, enrollment, and

retention flow. Forty-two participants were randomized, and forty-one completed the study

(Table 1). Forty-two participants completed cognitive outcomes, including the 1 participant who

dropped after their first period, for 41 CON and 42 SCF. Data from participants who completed

and were compliant (consumed >80% of supplement sachets measured by their compliance logs)

during at least one of their condition periods (PRE and POST for a treatment) were included in

the per-protocol analyses (38 CON and 39 SCF) for primary outcomes. For ERP P3 amplitudes,

there were three missing data points for CON (1=PRE, 2=POST) and seven missing for SCF

(2=PRE, 5=POST). Two participants could not provide fecal samples during the respective

collection periods, therefore, a total of 39 participants (38 CON, 37 SCF) were used for

secondary outcomes.

Cognitive outcomes

Behavioral Flanker Task performance was assessed using ACC and RT outcomes (**Table**

2). There were no significant treatment effects for ACC ($P = 0.32$) and no treatment x

congruency interaction ($P = 0.40$), with most participants maintaining high levels of task

accuracy ($\geq$92%) across all conditions. In contrast, RT outcomes revealed a significant main

effect of treatment ($P < 0.001$), with participants responding faster following SCF than CON.

Both baseline ($P < 0.001$; $\eta^2 = 0.27$) and RT interference ($P < 0.001$; $\eta^2 = 0.16$) were significant

covariates. *Post-hoc* comparisons using estimated marginal means indicated that SCF reduced

RTs by 8.26 ms in congruent trials (FDR $P = 0.03$, SE: 3.62, 95% CI: [1.03, 15.5 ms]) and by

11.81 ms for incongruent trials (FDR $P = 0.002$, SE: 3.61, 95% CI: [4.60 to 19.0 ms]) compared

to CON (**Supplemental Figure 5**). In a separate model with RT interference as the outcome with

baseline adjustment, participants who consumed SCF resolved interference more efficiently,

demonstrating a 4.33 ms faster resolution than CON ($P < 0.001$, SE: 1.27, 95% CI: [1.82, 6.83

ms]). ERP distribution of the P3 amplitude was visualized (**Supplemental Figure 6**), and mean

amplitude did not statistically differ between treatment groups ($P = 0.91$). No main congruency

effect was detected ($P = 0.67$) or in the treatment-by-congruency interaction ($P = 0.80$).

Similarly, the peak latency of the P3 component did not differ by treatment ($P = 0.29$) or the

interaction ($P = 0.38$); however, there was a congruency effect ($P = 0.02$). Standardized beta

coefficients are presented in Table 2.

There were no statistical differences between PANAS and PSS measures ($P > 0.29$;

Supplemental Table 1). The PSS had no statistical difference between conditions ($P=0.43$).

Performance across all CANTAB measures yielded null results (all $P > 0.13$; **Supplemental**

Table 2-5). POMS subscales and TMD, Godin physical activity scores, and the iPosition task

had no statistically significant treatment effects (all $P > 0.46$; **Supplemental Table 6**).

Metabolomics

No statistically significant differences in SCFA or BCFA concentrations were observed

(all $P > 0.12$; **Table 3**). Notably, SCF consumption numerically increased fecal acetate by

~11.3% ($P=0.12$, estimate: -0.12, SE: 0.08, 95% CI:[-0.28, 0.03]) compared to CON. Phenol,

indoles, and ammonia results are presented in **Supplemental Table 7**. Pooled total indole

concentrations (including indole, 2-methylindole, 3-methylindole, and 7-methylindole) tended to

be lower following SCF consumption ($P=0.09$, estimate: 0.23, SE: 0.13, 95% CI: [-0.04, 050]).

Phenol and ammonia concentrations did not differ between treatments (all $P > 0.26$).

Standardized beta coefficients are presented in Table 3.

Gastrointestinal symptoms

Gastrointestinal symptom severity scores remained within the absent-to-mild range for

most participants, with no significant differences observed between treatments for cramping,

nausea, reflux, rumbling, or burping (all $P > 0.17$; **Table 4**). However, gas severity increased

with SCF compared to CON ($P=0.01$), with 33% of SCF participants reporting moderate-to-

severe symptoms at the end-point compared to 16% in the CON group. Bloating severity also

increased after SCF (P=0.05). Stool characteristics, including self-reported consistency and ease

of passage measures, and pH did not differ between the CON and SCF conditions (all $P > 0.12$;

Supplemental Table 8).

16S Fecal microbiota

A significant treatment-by-time interaction was observed for richness ($P = 0.01$) and

post-hoc, demonstrating a difference between treatments at end-point (FDR $P < 0.001$, estimate:

29.11, SE: 8.16, 95% CI: [12.9, 45.3]) but not at baseline (FDR P=0.95). Shannon diversity had

no significant interaction effect (P=0.26) (**Supplemental Figure 7**). Standardized beta

coefficients are presented in **Table 5**. There was no significant treatment-by-time interaction in

Beta diversity measured by weighted UniFrac (R^2= 0.0072, P=0.35) or Bray-Curtis (R^2= 0.0055,

P=0.76; **Supplemental Figure 8**).

A total of 260 genera were initially detected in the dataset. After applying prevalence and

abundance filtering criteria, 128 genera were retained, and 14 met the significance threshold of

FDR < 0.05 (**Supplemental Figure 9**). Significant genera classified as *incertae sedis* and with

extremely low relative abundance at the end-point (11; <0.5%) are presented in **Supplemental**

Table 9. *Post-hoc* pairwise comparisons were performed on the log scale estimates from the log-

linked negative binomial models. *Parabacteroides* abundance had a significant treatment-by-

time interaction (FDR $P < 0.001$; Table 5, **Figure 2);** *post-hoc* pairwise comparison between

treatments at end-point demonstrated a 4.14-fold increase enrichment with SCF (FDR $P < 0.001$,

estimate: -1.42, SE: 0.16, 95% CI: [-1.74, -1.11]) with no difference detected between baseline

(FDR P=0.91, estimate: 0.02, SE: 0.16, 95% CI: [-0.29, 0.33]). *Fusicatenibacter* also had a

significant interaction effect (FDR $P < 0.001$); *post hoc* comparison between treatments at end-

points demonstrated a 2.64-fold increase with SCF (FDR $P<0.001$, estimate: -0.97, SE: 0.18,

95% CI: [-1.34, -0.60]), no difference at baseline (FDR $P=0.64$, estimate: 0.14, SE: 0.19, 95%

CI: [-0.23, 0.50]). *Dialister* similarly had an interaction effect (FDR $P = 0.02$); *post hoc*

demonstrated a 2.43-fold increase at end-point with SCF (FDR $P = 0.003$, estimate: -0.89, SE:

0.30, 95% CI: [-1.48, -0.30]), and also no difference at baseline (FDR $P=0.50$, estimate: 0.17,

SE: 0.26, 95% CI: [-0.33, 0.68]). Genus-level relative abundances and model FDR adjusted

treatment-by-time interaction and standardized beta coefficients are presented in Table 5

At the phylum level, 8 of the 15 detected phyla met filtering criteria, but none met the

significance threshold, phylum-level results shown in **Supplemental Table 10**.

Correlation analyses

As part of the third aim**,** the analyses tested relationships between microbial abundances,

SCFAs, and congruent RT in the Flanker task to explore task-related cognitive performance. The

Spearman correlation analysis explored relationships between reaction time for each congruency

type, SCFA concentrations, and *Parabacteroides* after SCF plotted in a heatmap (**Figure 3).**

Congruent RT was inversely associated with acetate (ρ = -0.328, $P=0.048$) and propionate

concentrations (ρ = -0.356, $P=0.031$). Incongruent RT was not significantly correlated with any

SCFA (*P*-values > 0.3). *Parabacteroides* relative abundance exhibited a significant positive

correlation with acetate (ρ = 0.343, $P=0.038$). However, *Parabacteroides* were not significantly

associated with congruent (ρ = -0.194, $P=0.25$) or incongruent RT ($P = 0.99$). In contrast,

Fusicatenibacter and *Dialister* showed numeric positive correlations with congruent RT (ρ =

0.30, $P=0.08$ and $\rho = 0.31$, $P=0.06$, respectively) demonstrated in **Supplementary Figure 10.**

Mediation analyses

This analysis (**Table 6**) evaluated fecal microbiota and metabolites as potential mediators

between treatment and congruent RT. Acetate did not significantly mediate the effect of

treatment on congruent RT (P=0.22, 95% CI: [-4.32, 0.78]). However, the direct impact of

treatment (ADE), representing effects independent of acetate, remained statistically significant

(P=0.03, 95% CI: [-22.99, -2.36]). The overall treatment effect (combining direct and mediated

pathways) was significant (P=0.01, 95% CI: [-24.27, -3.77]). The proportion mediated by acetate

was estimated at 11.4% (P=0.23, 95% CI: [-0.107, 0.54]). Sensitivity analysis for acetate

demonstrated that the confounding of both the mediator and outcome relationships would need to

explain approximately 4% of the shared variance to nullify the mediation effect.

Similarly, propionate, *Parabacteroides*, and *Fusicatenibacter* did not significantly

mediate the treatment's effect on congruent RT (all ACMEs $P \geq 0.1$), although the direct and

total effects of treatment remained significant in each case (all ADE and total effects $P \leq 0.05$).

Sensitivity analysis for propionate, *Fusicatenibacter*, and *Parabacteroides* similarly

demonstrated <2% shared variance to nullify the mediation effect.

Moderation analyses

For this analysis, we used 16S fecal microbiota (*Parabacteroides*) and fecal SCFA

(acetate and propionate) as moderators to evaluate their strength or direction on the relationship

between treatment and congruent RT. **Table 7** presents the standardized regression coefficients

from the moderation models. The relationship between treatment and congruent RT was

influenced by the abundance of *Parabacteroides*, exhibiting a statistically significant moderation

effect (β = 0.29, *P*=0.03). *Post-hoc* analyses using estimated marginal means and simple slopes

(**Figure 4**) also demonstrated a diminishing effect from *Parabacteroides*, significantly

moderating the treatment effect at –1 standard deviation (β_{-1} = –24.17, *P* < 0.001), marginally at

the centered mean level (β_0 = –9.95, *P*=0.10), but not at the higher end (β_{+1} = 4.27, *P*=0.68).

In vitro culturing of Pd measuring growth rates

The quick growth confirms the utilization of the simpler carbohydrates, and differing

growth rates at later time points for the fermentation of the fiber (**Figure 5a**). Peak OD_{600} was

highest in the SCF (0.60 abs at 13 hrs), followed by glucose (0.59 abs at 5.5 hrs) and CON (0.54

abs at 5 hrs). Mixed-effects modeling revealed significant main effects of media, time, and their

interaction (all FDR *P* < 0.001). *Post-hoc* comparisons confirmed a diauxic growth pattern in

SCF-treated cultures, which exhibited lower OD_{600} at 2 and 4 hrs (FDR *P* < 0.001) but higher

OD_{600} at 8 and 10 hrs compared to glucose and CON (FDR *P* < 0.001) (**Figure 5b**). No

significant differences were detected at 6 hrs and at the last time point (14 hrs). The blank control

remained significantly lower than all other treatments across all time points (FDR *P* < 0.001).

PICRUSt predicted metagenomic analyses

Unstratified KEGG Orthology (KO) analysis identified N-glycan biosynthesis and alpha-

linolenic acid metabolism pathways as significantly different between SCF and CON at end-

point (FDR *P* < 0.01; **Supplemental Figure 11a**). The corresponding unstratified EC analysis

also detected 23 enzyme functions differential between the treatments (FDR *P* < 0.05;

Supplemental Figure 11b). Significant pairwise differences were only detected between SCF at

end-point relative to all other time points, and no differences were found between CON and

baseline periods. From the MaAsLin2 analysis, we detected 2,701 carbohydrate-metabolism KOs

significantly associated with SCF at end-point (FDR $P < 0.05$), with the top 20 positive

coefficients shown in **Figure 6**. Additional pair-wise comparisons further gave resolution

between pairs detecting 1,778 significant KOs between PRE and POST SCF, four between PRE

and POST CON, and none between baseline periods. Among the top SCF-associated KOs, 18

were contributed by *Parabacteroides* and two by *Fusicatenibacter* (**Supplemental Figure 12**).

MetaPhlaN and HUMAnN analyses on Microbial Responder and Non-Responders

Summary analyses of genus-level relative abundances (**Supplemental Table 10,**

Supplemental Figure 13) suggest observable differences between SCF microbial responders

and non-responders. *Parabacteroides* was confirmed more abundant in responders' post-

intervention (13.6%) and remained low or undetectable in non-responders. At the species level

(**Supplemental Figure 14**), *Pd* and *P. merdae* appeared to increase in responders (10.9% and

2.7%, respectively) but were low or undetected in non-responders post-intervention (<0.5%).

Using HUMAnN, delta abundance analyses were conducted to examine microbial

contributions to carbohydrate metabolism-related KOs in responders and non-responders (**Figure**

7). Responders showed post-treatment increases in several gene families, including UDP-glucose

6-dehydrogenase, alpha-amylase, and hexokinase. In non-responders, KO abundances remained

relatively stable between PRE and POST time points. Genus- and species-level comparisons

(**Supplemental Figure 15** and **Figure 8,** respectively) demonstrate increased post-treatment

contributions from *Pd* across multiple carbohydrate-active genes, including glycoside hydrolases

(GHs), alpha-amylase, and hexokinase.

 CAZy analyses of GH in microbial Responders and Non-responders

When available and provided by CAZy databases, GH family and subfamilies were used

to compare log fold changes between responders and non-responders. From the 228 identified

GH families, we isolated those with positive log fold abundances in responders (**Supplemental**

Figure 16). Among the identified GH families, GH43_8, GH43_33, GH25, GH24, GH179,

GH13_9, GH130_2, and GH123 were abundantly present in responders and positively correlated

with *Parabacteroides* abundance (**Supplemental Figure 17**).

Discussion

In this randomized crossover trial, SCF consumption improved attentional inhibition,

demonstrated by faster RTs without sacrificing ACC measured by the modified flanker task. No

significant effects were observed for relational memory, perceived stress, mood, affect, or

neuropsychological function (as assessed by the iPosition task, PSS, POMS, PANAS, and

CANTAB, respectively). Microbiota analyses revealed an increase in *Parabacteroides* after

consuming SCF. There was a numeric increase in fecal acetate and mild gastrointestinal

intolerance symptoms. Functional analyses (predictive and shotgun metagenomics) suggested

enhanced carbohydrate metabolism, with *Pd* emerging as the primary SCF-responsive species. *In*

vitro culturing confirmed *Pd's* ability to metabolize SCF directly.

Few clinical trials have assessed the impact of dietary fiber on cognitive performance

while integrating microbiome analyses. Herein, SCF consumption selectively enhanced

attentional inhibition, a core executive function component, without impacting memory, mood,

or sacrificing accuracy. This suggests that SCF may support more efficient cognitive control,

particularly in resolving conflicting information and maintaining task-relevant focus. Our results

support emerging evidence that fibers may influence brain function via the gut-brain axis. Prior

studies have observed that other fibers, such as inulin, improve mood[26], but cognitive benefits

appear domain-specific and may depend on the fiber type, population, and study duration.

Consistent with previous SCF trials, *Parabacteroides* was enriched following the

intervention[16,71,72], and we identified *Pd* as the primary species. Notably, an inverse relationship

was observed between *Pd* and *Bacteroides vulgatus,* suggesting dynamic microbial competition

or adaption to SCF availability.

Functional predictions and metagenomic data revealed increased carbohydrate

metabolism and glycan degradation pathways following SCF consumption[73]. CAZy-based

functional annotation revealed GH enrichment within *Pd*, including GH13 and GH144, key

enzymes for metabolizing complex carbohydrates. *Parabacteroides* have been shown to harbor

carbohydrate-active enzymes, including GHs such as GH144, GH35, GH13, GH43 and

GH73[73,74]. GH144 and GH13, found specifically in *Pd*, contribute to β-1,2-

glucooligosaccharides hydrolysis, while GH13 is involved in the hydrolysis of α-1,6 glycosidic

bonds, allowing it to break down both complex and simple carbohydrate structures like SCF to

hold its place within the large intestine ecology[74].

Our *in vitro* experiment confirmed that *Pd* directly fermented SCF, with a diauxic

pattern, likely due to the mixture of SCF and non-fiber carbohydrates within the sachets. This

functional evidence, together with *in vivo* enrichment and metagenomic data, strongly supports

Pd's direct role in SCF fermentation.

Although fecal acetate only increased numerically with SCF consumption, SCFAs remain

strong candidates as mediators of gut-brain signaling. Indeed, SCFAs can positively affect

cognitive and affective processes through microbiota-dependent and independent

mechanisms[21,23]. For example, increasing colonic propionate through inulin-propionate ester

consumption influenced anticipatory brain reward response in healthy men[21], while

administering an SCFA mixture to the colon of healthy men for one-week reduced cortisol

response to an acute psychosocial stress challenge[21]. SCFAs in systemic circulation can cross the

blood-brain barrier (BBB) and directly impact brain health[23,75,76]. However, in our study,

mediation analyses did not support a direct causal role for SCFA or individual taxa in cognitive

performance. Moderation analyses indicated that the relationship between SCF consumption and

cognitive performance was moderated by *Parabacteroides* abundance. Interestingly, the

moderating influence diminished at higher abundance thresholds, where greater *Parabacteroides*

abundance was associated with slower RTs. These findings suggest threshold effects,

emphasizing the complexity of host-microbiome interactions.

In summary, our results demonstrated that SCF is selectively utilized by

Parabacteroides, which underpins cognitive benefits. A prebiotic is defined as "a substrate that

is selectively utilized by host microorganisms, conferring a health benefit"[75]. Within this

framework, our findings demonstrate SCF's prebiotic capability for modulating the gut

microbiota with meaningful implications for cognitive performance in healthy older adults.

Notably, *Parabacteroides* emerged as a consistent keystone taxon, enriched in 90% of

participants following SCF consumption, consistent with the Health-Associated Core Keystone

(HACK) index[76], which identified *Pd* as a core and stability-associated taxon[78]. Indeed, *Pd* has

been associated with health, including anti-inflammatory effects and gut barrier protection[77–79]

and bioactive metabolite production (i.e., gamma-aminobutyric acid (GABA)[80]), implicated in

gut-brain communication, which highlights *Pd's* potential as a next-generation probiotic

candidate[73,77–79,81,82].

Given that our sample was predominantly white, female, and highly educated, the

generalizability of these results is a limitation of the present work. Also, although metagenomic

sequencing was conducted to identify species and characterize shifts in microbiome functional

capacity following SCF consumption, these analyses were limited to a subsample of responders

and non-responders. Additionally, we did not collect blood, precluding assessment of systematic

SCFA or other circulating biomarkers. Finally, the fecal metabolite panel was limited in scope

and may have missed relevant compounds involved in gut-brain communication. Despite these

limitations, this study contributes novel evidence linking a specific fermentable fiber to selective

cognitive benefits, with mechanistic insights into microbiota responses and SCFA profiles.

Future studies should employ broader multi-omics analyses, dose-response designs, and systemic

biomarkers assessment to better elucidate the mechanisms underlying microbiota-mediated

cognitive outcomes and advance precision nutrition strategies.

Acknowledgments

We thank Dr. Michael J. Miller and Dr. Pratik Banerjee, and their graduate students, for

providing the *Pd* strain, facility, and equipment to perform the *in vitro* growth culturing

component of this research. We would like to thank the graduate and undergraduate research

assistants from the Holscher and Khan laboratories for their assistance during the clinical

appointments and data entry.

Author Disclosures

The authors report no conflict of interest.

Author contributions

The authors' responsibilities were as follows – HDH, NAK, DAA, TAH: designed the

research; MDB, TM: recruited and enrolled participants and coordinated study procedures;

DAA: conducted the *in vitro* experiment; DAA, TAH, SM, TM, RS: conducted the experiments

and testing appointments; MA, DR, DAA: managed biological samples collection and storages;

DAA, TAH: managed study data; DAA, NS: prepared data for bioinformatic pipelines; DAA,

TAH: analyzed the data: DAA, TAH, NAK, HDH: wrote the manuscript; NAK, HDH: had

primary responsibility for final content; and all authors: read and approved the final manuscript.

References

1.   Morris MC, Wang Y, Barnes LL, Bennett DA, Dawson-Hughes B, Booth SL. Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study. *Neurology*. 2018;90(3):E214-E222. doi:10.1212/WNL.0000000000004815

2.   Perim Baldo M, Aboussaleh Y, Turrini A, et al. Adherence to a Mediterranean-Style Diet and effects on Cognition in Adults: A Qualitative evaluation and Systematic Review of Longitudinal and Prospective Trials. 2016;3:1. doi:10.3389/fnut.2016.00022

3.   Khan NA, Raine LB, Donovan SM, Hillman CH. IV. The cognitive implications of obesity and nutrition in childhood. *Monogr Soc Res Child Dev*. 2014;79(4):51-71. doi:10.1111/mono.12130

4.   Fleming SA, Monaikul S, Patsavas AJ, Waworuntu R V., Berg BM, Dilger RN. Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig. *Nutr Neurosci*. 2019;22(7):499-512. doi:10.1080/1028415X.2017.1415280

5.   Gronier B, Savignac HM, Miceli M Di, et al. Increased cortical neuronal responses to NMDA and improved attentional set-shifting performance in rats following prebiotic (B-GOS s) ingestion. doi:10.1016/j.euroneuro.2017.11.001

6.   Khan NA, Raine LB, Drollette ES, Scudder MR, Kramer AF, Hillman CH. Dietary Fiber Is Positively Associated with Cognitive Control among Prepubertal Children. *J Nutr*. 2015;145(1):143-149. doi:10.3945/JN.114.198457

7.   Hassevoort KM, Lin AS, Khan NA, Hillman CH, Cohen NJ. Added sugar and dietary fiber consumption are associated with creativity in preadolescent children. *Nutr Neurosci*. 2020;23(10):791-802. doi:10.1080/1028415X.2018.1558003

8.   Naveed S, Venäläinen T, Eloranta AM, et al. Associations of dietary carbohydrate and fatty acid intakes with cognition among children. *Public Health Nutr*. 2020;23(9):1657-1663. doi:10.1017/S1368980019003860

9.   Shuan W, Tan K, Fen P, et al. The Role of Soluble Corn Fiber on Glycemic and Insulin Response. doi:10.3390/nu12040961

10.   Jakeman SA, Henry CN, Martin BR, et al. Soluble corn fiber increases bone calcium retention in postmenopausal women in a dose-dependent manner: A randomized crossover trial. *American Journal of Clinical Nutrition*. 2016;104(3):837-843. doi:10.3945/ajcn.116.132761

11.   Klosterbuer AS, Hullar MAJ, Li F, et al. Gastrointestinal effects of resistant starch, soluble maize fibre and pullulan in healthy adults. doi:10.1017/S0007114513000019

12.   Stewart ML, Nikhanj SD, Timm DA, Thomas W, Slavin JL. Evaluation of the effect of four fibers on laxation, gastrointestinal tolerance and serum markers in healthy humans. *Ann Nutr Metab*. 2010;56(2):91-98. doi:10.1159/000275962

13.   LinAmy AHM, Nichols BL, Quezada-Calvillo R, et al. Unexpected high digestion rate of cooked starch by the Ct-maltase-glucoamylase small intestine mucosal α-glucosidase subunit. *PLoS One*. 2012;7(5). doi:10.1371/journal.pone.0035473

14.   Vester Boler BM, Rossoni Serao MC, Bauer LL, et al. Digestive physiological outcomes related to polydextrose and soluble maize fibre consumption by healthy adult men. *British Journal of Nutrition*. 2011;106(12):1864-1871. doi:10.1017/S0007114511002388

15.   Maathuis A, Venema K, Hoffman A, Evans A, Sanders L. The effect of the undigested fraction of maize products on the activity and composition of the microbiota determined in

a dynamic in vitro model of the human proximal large intestine. *J Am Coll Nutr*.
2009;28(6):657-666. doi:10.1080/07315724.2009.10719798

16. Whisner CM, Martin BR, Nakatsu CH, et al. Soluble corn fiber increases calcium
absorption associated with shifts in the gut microbiome: A randomized dose-response trial
in free-living pubertal females. *Journal of Nutrition*. 2016;146(7):1298-1306.
doi:10.3945/jn.115.227256

17. Arroyo MC, Laurie I, Rotsaert C, Marzorati M, Risso D, Karnik K. Age-Dependent
Prebiotic Effects of Soluble Corn Fiber in M-SHIME® Gut Microbial Ecosystems. *Plant*
Foods for Human Nutrition. 2023;78(1):213-220. doi:10.1007/s11130-023-01043-z

18. Diamond A. Executive functions. *Annu Rev Psychol*. 2013;64:135-168.
doi:10.1146/annurev-psych-113011-143750

19. Duncan-Johnson CC. P300 latency: A new metric of information processing.
Psychophysiology. 1981;18(3):207-215. doi:10.1111/j.1469-8986.1981.tb03020.x

20. Polich J. Updating P300: An integrative theory of P3a and P3b. *Clinical Neurophysiology*.
2007;118(10):2128-2148. doi:10.1016/j.clinph.2007.04.019

21. La Torre D, Verbeke K, Dalile B. Dietary fibre and the gut–brain axis: microbiota-
dependent and independent mechanisms of action. *Gut Microbiome*. 2021;2.
doi:10.1017/gmb.2021.3

22. Dalile B, Fuchs A, La Torre D, Vervliet B, Van Oudenhove L, Verbeke K. Colonic
butyrate administration modulates fear memory but not the acute stress response in men:
A randomized, triple-blind, placebo-controlled trial. *Prog Neuropsychopharmacol Biol*
Psychiatry. 2024;131. doi:10.1016/j.pnpbp.2024.110939

23. Cheng J, Hu H, Ju Y, et al. Gut microbiota-derived short-chain fatty acids and depression:
deep insight into biological mechanisms and potential applications. *Gen Psychiatr*.
2024;37(1). doi:10.1136/gpsych-2023-101374

24. Luqman A, He M, Hassan A, et al. Mood and microbes: a comprehensive review of
intestinal microbiota's impact on depression. *Front Psychiatry*. 2024;15.
doi:10.3389/fpsyt.2024.1295766

25. Haskell CF, Scholey AB, Jackson PA, et al. Cognitive and mood effects in healthy
children during 12 weeks' supplementation with multi-vitamin/minerals. *British Journal*
of Nutrition. 2008;100(5):1086-1096. doi:10.1017/S0007114508959213

26. Leyrolle Q, Cserjesi R, D.G.H. Mulders M, et al. Prebiotic effect on mood in obese
patients is determined by the initial gut microbiota composition: A randomized, controlled
trial. *Brain Behav Immun*. 2021;94:289-298. doi:10.1016/j.bbi.2021.01.014

27. Erdfelder E, FAul F, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1:
Tests for correlation and regression analyses. *Behav Res Methods*. 2009;41(4):1149-1160.
doi:10.3758/BRM.41.4.1149

28. Edwards CG, Walk AM, Cannavale CN, et al. Dietary choline is related to neural
efficiency during a selective attention task among middle-aged adults with overweight and
obesity. *https://doi.org/101080/1028415X20191623456*. 2019;24(4):269-278.
doi:10.1080/1028415X.2019.1623456

29. Chatrian GE, Lettich E, Nelson PL. American Journal of EEG Technology Ten Percent
Electrode System for Topographic Studies of Spontaneous and Evoked EEG Activities
Ten Percent Electrode System for Topographic Studies of Spontaneous and Evoked EEG
Activities. Published online 2015. doi:10.1080/00029238.1985.11080163

30. Delorme A, Makeig S. EEGLAB: An open source toolbox for analysis of single-trial EEG
dynamics including independent component analysis. *J Neurosci Methods*. 2004;134(1):9-
21. doi:10.1016/J.JNEUMETH.2003.10.009

31. Lopez-Calderon J, Luck SJ. ERPLAB: An open-source toolbox for the analysis of event-
related potentials. *Front Hum Neurosci*. 2014;8(1 APR):213.
doi:10.3389/FNHUM.2014.00213/BIBTEX

32. Kamijo K, Pontifex MB, Khan NA, et al. The association of childhood obesity to
neuroelectric indices of inhibition. *Psychophysiology*. 2012;49(10):1361-1371.
doi:10.1111/J.1469-8986.2012.01459.X

33. Walk AM, Edwards CG, Baumgartner NW, et al. The role of retinal carotenoids and age
on neuroelectric indices of attentional control among early to middle-aged adults. *Front
Aging Neurosci*. 2017;9(JUN):183. doi:10.3389/FNAGI.2017.00183/BIBTEX

34. Luck SJ, Gaspelin N. How to get statistically significant effects in any ERP experiment
(and why you shouldn't). *Psychophysiology*. 2017;54(1):146-157.
doi:10.1111/PSYP.12639

35. Pontifex MB. Stylized Topographic Map Plugin for EEGLAB/ERPLAB.

36. Horecka KM, Dulas MR, Schwarb H, Lucas HD, Duff M, Cohen NJ. Reconstructing
relational information. *Hippocampus*. 2018;28(2):164-177. doi:10.1002/hipo.22819

37. Stephen J. Gibson. The Measurement of Mood States in Older Adults. *The Journals of
Gerontology: Series B*. 1997;52B(4):167-174.

38. Humboldt S von, Monteiro A, Leal I. Validation of the PANAS: A Measure of Positive
and Negative Affect for Use with Cross-National Older Adults. *Rev Eur Stud*.
2017;9(2):10. doi:10.5539/res.v9n2p10

39. Lee EH. Review of the psychometric evidence of the perceived stress scale. *Asian Nurs
Res (Korean Soc Nurs Sci)*. 2012;6(4):121-127. doi:10.1016/j.anr.2012.08.004

40. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2:
High-resolution sample inference from Illumina amplicon data. *Nat Methods*.
2016;13(7):581-583. doi:10.1038/nmeth.3869

41. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible
microbiome data science using QIIME 2. *Nat Biotechnol*. 2019;37(8):852-857.
doi:10.1038/s41587-019-0209-9

42. Yilmaz P, Parfrey LW, Yarza P, et al. The SILVA and "all-species Living Tree Project
(LTP)" taxonomic frameworks. *Nucleic Acids Res*. 2014;42(D1). doi:10.1093/nar/gkt1209

43. Morton JT, Marotz C, Washburne A, et al. Establishing microbial composition
measurement standards with reference frames. *Nat Commun*. 2019;10(1).
doi:10.1038/s41467-019-10656-5

44. McMurdie PJ, Holmes S. Phyloseq: An R Package for Reproducible Interactive Analysis
and Graphics of Microbiome Census Data. *PLoS One*. 2013;8(4).
doi:10.1371/journal.pone.0061217

45. Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome
functions. *Nat Biotechnol*. 2020;38(6):685-688. doi:10.1038/s41587-020-0548-6

46. Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial
communities using 16S rRNA marker gene sequences. *Nat Biotechnol*. 2013;31(9):814-
821. doi:10.1038/nbt.2676

47. Yang C, Mai J, Cao X, Burberry A, Cominelli F, Zhang L. ggpicrust2: an R package for
PICRUSt2 pre-dicted functional profile analysis and visualiza-tion. *Bioinformatics,*
YYYY.:0-0. doi:10.1093/bioinformatics/xxxxx

48. Mallick H, Rahnavard A, McIver LJ, et al. Multivariable association discovery in
population-scale meta-omics studies. *PLoS Comput Biol*. 2021;17(11).
doi:10.1371/journal.pcbi.1009442

49. Kenneth Helrich. *Official Methods for Analysis of the Association of Official Analytical*
Chemists.; 1990.

50. Chaney AL, MEP. Modified Reagents for Determination of Urea and Ammonia. *Clin*
Chem. 1962;8(2):130-132.

51. Holscher HD, Doligale JL, Bauer LL, et al. Gastrointestinal tolerance and utilization of
agave inulin by healthy adults. *Food Funct*. 2014;5(6):1142-1149.
doi:10.1039/c3fo60666j

52. Flickinger EA, Schreijen EMWC, Patil AR, et al. Nutrient digestibilities, microbial
populations, and protein catabolites as affected by fructan supplementation of dog diets
Get access Arrow. *J Anim Sci*. 2003;81(8):2008-2018.

53. Holscher HD, Chumpitazi BP, Dahl WJ, et al. Perspective: Assessing Tolerance to
Nondigestible Carbohydrate Consumption. *Advances in Nutrition*. 2022;13(6):2084-2097.
doi:10.1093/advances/nmac091

54. García-Bayona L, Comstock LE. Streamlined genetic manipulation of diverse bacteroides
and parabacteroides isolates from the human gut microbiota. *mBio*. 2019;10(4).
doi:10.1128/mBio.01762-19

55. Blanco-Míguez A, Beghini F, Cumbo F, et al. Extending and improving metagenomic
taxonomic profiling with uncharacterized species using MetaPhlAn 4. *Nat Biotechnol*.
2023;41(11):1633-1644. doi:10.1038/s41587-023-01688-w

56. Beghini F, McIver LJ, Blanco-Míguez A, et al. Integrating taxonomic, functional, and
strain-level profiling of diverse microbial communities with biobakery 3. *Elife*. 2021;10.
doi:10.7554/eLife.65088

57. Drula E, Garron ML, Dogan S, Lombard V, Henrissat B, Terrapon N. The carbohydrate-
active enzyme database: Functions and literature. *Nucleic Acids Res*. 2022;50(D1):D571-
D577. doi:10.1093/nar/gkab1045

58. Cantarel BI, Coutinho PM, Rancurel C, Bernard T, Lombard V, Henrissat B. The
Carbohydrate-Active EnZymes database (CAZy): An expert resource for glycogenomics.
Nucleic Acids Res. 2009;37(SUPPL. 1). doi:10.1093/nar/gkn663

59. Zheng J, Ge Q, Yan Y, Zhang X, Huang L, Yin Y. DbCAN3: Automated carbohydrate-
Active enzyme and substrate annotation. *Nucleic Acids Res*. 2023;51(W1):W115-W121.
doi:10.1093/nar/gkad328

60. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest Package: Tests in Linear Mixed
Effects Models. *J Stat Softw*. 2017;82(13):1-26. doi:10.18637/JSS.V082.I13

61. R Core Team. R: A language and environment for statistical computing. Published online
2013.

62. Czech L, Barbera P, Stamatakis A. Genesis and Gappa: Processing, analyzing and
visualizing phylogenetic (placement) data. *Bioinformatics*. 2020;36(10):3263-3265.
doi:10.1093/bioinformatics/btaa070

63. Louca S, Doebeli M. Efficient comparative phylogenetics on large trees. *Bioinformatics*.
2018;34(6):1053-1055. doi:10.1093/bioinformatics/btx701

64.   Ye Y, Doak TG. A parsimony approach to biological pathway reconstruction/inference for
genomes and metagenomes. *PLoS Comput Biol*. 2009;5(8).
doi:10.1371/journal.pcbi.1000465

65.   Kwak SK, Kim JH. Statistical data preparation: Management of missing values and
outliers. *Korean J Anesthesiol*. 2017;70(4):407-411. doi:10.4097/kjae.2017.70.4.407

66.   Kafadar K. John Tukey and Robustness. *Statistical Science*. 2003;3(18(3)):319-331.
doi:1076102419

67.   Zhang X, Mallick H, Tang Z, et al. Negative binomial mixed models for analyzing
microbiome count data. *BMC Bioinformatics*. 2017;18(1). doi:10.1186/s12859-016-1441-
7

68.   Sweeny AR, Lemon H, Ibrahim A, et al. A mixed-model approach for estimating drivers
of microbiota community composition and differential taxonomic abundance. *mSystems*.
Published online July 25, 2023. doi:10.1128/msystems.00040-23

69.   Jamieson PE, Smart EB, Bouranis JA, et al. Gut enterotype-dependent modulation of gut
microbiota and their metabolism in response to xanthohumol supplementation in healthy
adults. *Gut Microbes*. 2024;16(1). doi:10.1080/19490976.2024.2315633

70.   Zwietering MH, Jongenburger I, Rombouts FM, Van ' K, Riet T. *Modeling of the
Bacterial Growth Curve PUm*.; 1990. https://journals.asm.org/journal/aem

71.   Timm DA, Thomas W, Boileau TW, Williamson-Hughes PS, Slavin JL. Polydextrose and
soluble corn fiber increase five-day fecal wet weight in healthy men and women. *Journal
of Nutrition*. 2013;143(4):473-478. doi:10.3945/jn.112.170118

72.   Hooda S, Vester Boler BM, Rossoni Serao MC, et al. 454 pyrosequencing reveals a shift
in fecal microbiota of healthy adult men consuming polydextrose or soluble corn fiber.
Journal of Nutrition. 2012;142(7):1259-1265. doi:10.3945/jn.112.158766

73.   Shimizu H, Nakajima M, Miyanaga A, et al. Characterization and Structural Analysis of a
Novel exo-Type Enzyme Acting on β-1,2-Glucooligosaccharides from Parabacteroides
distasonis. *Biochemistry*. 2018;57(26):3849-3860. doi:10.1021/acs.biochem.8b00385

74.   Ducarmon QR, Karcher N, Tytgat HLP, et al. Large-scale computational analyses of gut
microbial CAZyme repertoires enabled by Cayman. Published online January 8, 2024.
doi:10.1101/2024.01.08.574624

75.   Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International
Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the
definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol*. 2017;14(8):491-502.
doi:10.1038/nrgastro.2017.75

76.   Goel A, Shete O, Goswami S, et al. Toward a health-associated core keystone index for
the human gut microbiome. *Cell Rep*. 2025;44(3):115378.
doi:10.1016/j.celrep.2025.115378

77.   Cui Y, Zhang L, Wang X, et al. Roles of intestinal Parabacteroides in human health and
diseases. *FEMS Microbiol Lett*. 2022;369(1). doi:10.1093/femsle/fnac072

78.   Cuffaro B, Boutillier D, Desramaut J, et al. Characterization of Two Parabacteroides
distasonis Candidate Strains as New Live Biotherapeutics against Obesity. *Cells*.
2023;12(9). doi:10.3390/cells12091260

79.   Ezeji JC, Sarikonda DK, Hopperton A, et al. Parabacteroides distasonis: intriguing
aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and
probiotic roles in human health. *Gut Microbes*. 2021;13(1).
doi:10.1080/19490976.2021.1922241

80.   Liang Z, Di N, Li L, Yang D. Gut microbiota alterations reveal potential gut–brain axis
changes in polycystic ovary syndrome. *J Endocrinol Invest*. 2021;44(8):1727-1737.
doi:10.1007/s40618-020-01481-5
81.   Wei W, Wong CC, Jia Z, et al. Parabacteroides distasonis uses dietary inulin to suppress
NASH via its metabolite pentadecanoic acid. *Nat Microbiol*. 2023;8(8):1534-1548.
doi:10.1038/s41564-023-01418-7
82.   Liu D, Zhang S, Li S, et al. Indoleacrylic acid produced by Parabacteroides distasonis
alleviates type 2 diabetes via activation of AhR to repair intestinal barrier. *BMC Biol*.
2023;21(1). doi:10.1186/s12915-023-01578-2

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

Tables

Table 1. Baseline Demographic and Clinical Characteristics of Participants Randomized to Maltodextrin or Soluble Corn Fiber Treatments

	Overall N = 42	Maltodextrin N = 21	Soluble Corn Fiber N = 21
Education			
High School Graduate	2 (4.8%)	0 (0%)	2 (9.5%)
Some College	6 (14%)	3 (14%)	3 (14%)
Bachelor's Degree	13 (31%)	8 (38%)	5 (24%)
Advanced Degree	21 (50%)	10 (48%)	11 (52%)
Ethnicity			
Asian	6 (14%)	3 (14%)	3 (14%)
Black or African American	3 (7.1%)	1 (4.8%)	2 (9.5%)
Mixed or Other	1 (2.4%)	0 (0%)	1 (4.8%)
White (Caucasian)	32 (76%)	17 (81%)	15 (71%)
Latino	1 (2.4%)	1 (4.8%)	0 (0%)
Sex			
Female	28 (67%)	15 (71%)	13 (62%)
Male	14 (33%)	6 (29%)	8 (38%)
Age (years)	56.2 ± 7.3	54.8 ± 6.2	57.5 ± 8.2
Fiber per 1000kcal	11.4 ± 3.4	12.0 ± 3.3	10.8 ± 3.5
BMI (kg/m²)	25.9 ± 4.0	25.4 ± 3.7	26.3 ± 4.2
Income			
Less than $10,000	1 (2.4%)	0 (0%)	1 (4.8%)
$11,000-20,000	0 (0%)	0 (0%)	0 (0%)
$21,000-30,000	0 (0%)	0 (0%)	0 (0%)
$31,000-40,000	3 (7.1%)	1 (4.8%)	2 (9.5%)
$41,000-50,000	3 (7.1%)	1 (4.8%)	2 (9.5%)
$51,000-60,000	3 (7.1%)	2 (9.5%)	1 (4.8%)
$61,000-70,000	4 (9.5%)	1 (4.8%)	3 (14%)
$71,000-80,000	5 (12%)	4 (19%)	1 (4.8%)
$81,000-90,000	1 (2.4%)	1 (4.8%)	0 (0%)
$91,000-100,000	7 (16.7%)	4 (19%)	3 (14%)
Greater than $100,000	15 (35.7%)	7 (33%)	8 (38%)

Baseline characteristics of participants enrolled and randomized into the clinical trial (N = 42), stratified by initial treatment assignment. Continuous variables are reported as mean ± standard deviation; categorical variables are reported as number of participants and percentage within each group [n (%)].

Table 2. Behavioral and ERP Outcomes During the Flanker Task Across Timepoints and

Treatment Conditions

	Maltodextrin		Soluble Corn Fiber		
	PRE	**POST**	**PRE**	**POST**	
Behavioral Flanker	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	*Treatment*
Accuracy					*P:* 0.32
Congruent	96.87 ± 0.52 *(39)*	95.50 ± 1.37 *(39)*	97.04 ± 0.48 *(40)*	97.64 ± 0.45 *(40)*	95% CI: [-0.10, 0.49]
Incongruent	92.37 ± 1.00 *(39)*	92.04 ± 1.53 *(39)*	93.60 ± 0.79 *(40)*	94.35 ± 0.70 *(40)*	β: 0.20
Reaction Time					**_P:_ <0.001*****
Congruent	395.13 ± 5.79 *(39)*	**398.44 ± 6.69**[a] *(39)*	400.71 ± 6.22 *(40)*	**389.49 ± 5.52**[b] *(40)*	95% CI: [-0.34, -0.02]
Incongruent	430.89 ± 6.62 *(39)*	**437.29 ± 7.77**[a] *(39)*	435.43 ± 6.88 *(40)*	**423.99 ± 6.35**[b] *(40)*	β: -0.18
ERP Flanker					
Amplitude					*P:* 0.96
Congruent	5.96 ± 1.73 *(39)*	6.78 ± 0.68 *(36)*	6.64 ± 0.60 *(39)*	7.07 ± 0.77 *(37)*	95% CI: [-0.31, 0.21]
Incongruent	6.36 ± 1.64 *(39)*	6.77 ± 0.69 *(36)*	7.14 ± 0.65 *(39)*	7.50 ± 0.79 *(37)*	β: -0.05
Peak Latency					*P:* 0.28
Congruent	385.68 ± 6.71 *(39)*	399.11 ± 10.18 *(36)*	394.49 ± 7.29 *(39)*	398.06 ± 7.99 *(37)*	95% CI: [-0.12, 0.17]
Incongruent	424.43 ± 8.34 *(39)*	442.88 ± 11.70 *(36)*	438.54 ± 9.90 *(39)*	428.76 ± 8.27 *(37)*	β: 0.02

Mean ± standard error of the mean (SEM) and n values for behavioral and electrophysiological measures recorded during the Flanker task under congruent and incongruent conditions, stratified by treatment and timepoint. Measures include accuracy (%), reaction time (ms), P3 amplitude (μV), and P3 peak latency (ms). Linear mixed effect models included participant as a random effect, treatment-by-congruency interaction, and baseline covariate for the respective outcome; ACC and RT models included the flanker effect (Incongruent-Congruent). *Post-hoc* pairwise

1052   comparisons conducted within each congruency condition if Treatment $P < 0.05$. In the table, a, b

1053   indicates significant differences within congruency conditions between treatments at end-point

1054   after adjusting for baseline. *P* significance threshold used were as follows: '***' <0.001, '**'

1055 <0.01, '*' <0.05, '†' <0.1. Standardization was performed by refitting models with z-scored

1056   predictors (method = "refit") using parameters (v0.25) package.

1057

1058

1059

 Table 3. Fecal Volatile Fatty Acid Concentrations by Treatment and Timepoint

	Maltodextrin		Soluble Corn Fiber				
	PRE	**POST**	**PRE**	**POST**			
Short Chain Fatty Acids	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	*P*	β_{Std}	*95% CI*
Butyrate	43.28 ± 4.56 *(38)*	43.90 ± 5.26 *(37)*	38.77 ± 4.58 *(37)*	40.09 ± 3.18 *(37)*	0.83	0.07	[-0.30, 0.45]
Acetate	175.71 ± 13.85 *(38)*	181.71 ± 13.50 *(37)*	165.31 ± 13.24 *(37)*	202.17 ± 14.94 *(37)*	0.12	0.09	[-0.03, 0.22]
Propionate	48.11 ± 3.98 *(38)*	50.80 ± 4.40 *(37)*	47.48 ± 4.32 *(37)*	55.58 ± 4.72 *(37)*	0.19	0.09	[-0.05, 0.23]
Total SCFAs	267.10 ± 21.46 *(38)*	273.04 ± 21.97 *(37)*	255.38 ± 20.58 *(37)*	297.84 ± 22.30 *(37)*	0.13	0.09	[-0.03, 0.23]
Branched Chain Fatty Acids							
Valerate	6.44 ± 0.59 *(38)*	5.99 ± 0.47 *(37)*	6.00 ± 0.47 *(37)*	5.68 ± 0.48 *(37)*	0.58	-0.05	[-0.22, 0.11]
Isobutyrate	6.62 ± 0.54 *(38)*	5.97 ± 0.39 *(36)*	6.29 ± 0.52 *(37)*	5.22 ± 0.33 *(37)*	0.16	-0.26	[-0.61, 0.10]
Isovalerate	9.49 ± 0.82 *(38)*	8.30 ± 0.57 *(36)*	8.66 ± 0.69 *(37)*	7.35 ± 0.54 *(37)*	0.42	-0.14	[-0.48, 0.20]
Total BCFAs	22.55 ± 1.83 *(38)*	20.37 ± 1.31 *(37)*	20.96 ± 1.56 *(37)*	18.25 ± 1.14 *(37)*	0.64	-0.03	[-0.15, 0.10]

Fecal volatile fatty acids measured pre- and post-intervention for each condition arm. Values

represent mean ± standard error of the mean (SEM), with sample sizes in parentheses. *P*-values,

standardized beta coefficients (β_{Std}), and 95% confidence intervals (CI) are derived from linear

mixed effects models with a random intercept for participant ID and fixed effects for treatment

and baseline (PRE) values. Standardization was performed by refitting models with z-scored

predictors (method = "refit") using parameters (v0.25) package.

1067

1068   **Table 4. Self-Reported Gastrointestinal Symptoms by Treatment and Timepoint**

	Maltodextrin		Soluble Corn Fiber		
	PRE	**POST**	**PRE**	**POST**	
GI Symptoms	Median [IQR] *(n)*	Median [IQR] *(n)*	Median [IQR] *(n)*	Median [IQR] *(n)*	*P*
Gas	1.57 [0.84] *(39)*	**1.43 [1.00]** *(39)*	1.57 [0.97] *(38)*	**1.93 [1.00]** *(38)*	**0.01***
Cramping	1.00 [0.00] *(39)*	1.00 [0.00] *(39)*	1.00 [0.00] *(38)*	1.00 [0.14] *(38)*	0.91
Bloating	1.00 [0.14] *(39)*	1.00 [0.14] *(39)*	1.00 [0.14] *(38)*	1.00 [0.32] *(38)*	0.05†
Nausea	1.00 [0.00] *(39)*	1.00 [0.00] *(39)*	1.00 [0.00] *(38)*	1.00 [0.00] *(38)*	0.17
Reflux	1.00 [0.00] *(39)*	1.00 [0.00] *(39)*	1.00 [0.03] *(38)*	1.00 [0.00] *(38)*	0.84
Rumbling	1.00 [0.16] *(39)*	1.00 [0.16] *(39)*	1.00 [0.17] *(38)*	1.00 [0.41] *(38)*	0.68
Burping	1.00 [0.16] *(39)*	1.00 [0.00] *(39)*	1.00 [0.28] *(38)*	1.00 [0.17] *(38)*	0.70

1069   Median and interquartile range (IQR) scores for gastrointestinal symptoms reported at baseline

1070   (PRE) and post-intervention (POST) for each condition. Symptom severity was rated on a 4-

1071   point scale (1 = Absent, 2 = Mild, 3 = Moderate, 4 = Severe). Between-treatment comparisons of

1072   change scores were assessed using paired Wilcoxon signed-rank tests. Reported values include

1073   *P*-values. †$P < 0.1$, *$P < 0.05$.

1074

1075

1076

1077

1078

1079

Table 5. 16S Alpha Diversity and Differential Abundance of Genera from Human Fecal

Samples by Treatment and Timepoint

	Maltodextrin		Soluble Corn Fiber				
	PRE	**POST**	**PRE**	**POST**			
Genus (% of sequence)	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	FDR *P*	*β*$_{Std}$	*95% CI*
Bacteroides	25.23 ± 1.77 *(38)*	23.70 ± 1.90 *(38)*	27.32 ± 2.06 *(37)*	22.60 ± 2.07 *(37)*	0.11	-0.15	[-0.34, 0.05]
Faecalibacterium	10.19 ± 1.02 *(38)*	10.12 ± 1.11 *(38)*	8.66 ± 1.15 *(37)*	11.02 ± 1.30 *(37)*	0.47	0.23	[-0.18, 0.64]
Parabacteroides	2.52 ± 0.35[a] *(38)*	**2.06 ± 0.24[a]** *(38)*	2.09 ± 0.26[a] *(37)*	**8.37 ± 0.98[b]** *(37)*	**<0.001*****	1.44	[1.01, 1.88]
Alistipes	3.46 ± 0.51 *(38)*	2.82 ± 0.35 *(38)*	3.88 ± 0.59 *(37)*	3.96 ± 0.69 *(37)*	0.50	0.08	[-0.31, 0.46]
Blautia	3.76 ± 0.50 *(38)*	4.52 ± 0.61 *(38)*	3.54 ± 0.42 *(37)*	3.24 ± 0.50 *(37)*	0.10†	-0.27	[-0.52,-0.02]
Agathobacter	4.16 ± 0.88 *(38)*	5.97 ± 1.17 *(38)*	3.99 ± 0.85 *(37)*	2.80 ± 0.58 *(37)*	0.11	-0.46	[-0.91, 0.01]
Subdoligranulum	2.31 ± 0.29 *(38)*	2.54 ± 0.38 *(38)*	3.24 ± 0.58 *(37)*	2.69 ± 0.49 *(37)*	0.83	-0.24	[-0.68, 0.19]
Prevotella	0.87 ± 0.41 *(38)*	1.64 ± 0.74 *(38)*	1.60 ± 0.89 *(37)*	2.13 ± 1.04 *(37)*	0.53	-0.22	[-0.81, 0.37]
Dialister	1.34 ± 0.44[a] *(38)*	**1.46 ± 0.51[a]** *(38)*	0.93 ± 0.34[a] *(37)*	**2.10 ± 0.63[b]** *(37)*	**0.02***	1.06	[0.29, 1.83]
Bifidobacterium	2.50 ± 0.53 *(38)*	2.69 ± 0.53 *(38)*	2.12 ± 0.52 *(37)*	2.09 ± 0.41 *(37)*	0.92	0.09	[-0.51, 0.70]
Fusicatenibacter	0.60 ± 0.10[a] *(38)*	**0.67 ± 0.09[a]** *(38)*	0.53 ± 0.11[a] *(37)*	**1.79 ± 0.28[b]** *(37)*	**<0.001*****	1.10	[0.59, 1.61]
Alpha diversity metrics					*P*	*β*$_{Std}$	*95% CI*
Richness	439.92 ± 19.80[a] *(38)*	**438.68 ± 18.21[a]** *(38)*	443.57 ± 17.57[a] *(37)*	**413.73 ± 18.56[b]** *(37)*	**0.01***	-0.25	[-0.45,-0.05]
Shannon	3.89 ± 0.06 *(38)*	3.88 ± 0.06 *(38)*	3.81 ± 0.06 *(37)*	3.71 ± 0.07 *(37)*	0.26	-0.20	[-0.56, 0.15]

Values represent mean ± standard error of the mean (SEM), with sample sizes in parentheses.

For 16S data, FDR-adjusted *P*-values reflect the treatment-by-time interaction from generalized

linear mixed effect models with a negative binomial distribution and log-link. For alpha

diversity, *P*-values represent treatment-by-time interactions from linear mixed effect model. All

models included a random intercept for participant ID. Standardized beta coefficients (β_{Std}), and

95% confidence intervals (CI) was performed by refitting models with z-scored predictors

(method = "refit") using parameters (v0.25) package. *Post-hoc* pairwise analysis was conducted

on genera meeting the FDR *P* < 0.05 (16S) or *P* < 0.05 (alpha diversity) for the interaction term.

Superscript letters (a, b) indicate significant pairwise differences between treatments within

timepoints after BH adjustment. Significance *P* thresholds: †*P* < 0.1, *P < 0.05, ***P < 0.001.

1092

1093

Table 6. Mediation Effects of 16S Fecal Microbiota and Metabolites on the Relationship Between SCF and Congruent Reaction Time at end-point

Mediator	Flanker Task	Effect	Estimate	[95% CI]	*P*
Parabacteroides	Congruent RT	Mediation effect	0.24	[-5.32, 4.85]	0.91
		Direct effect	-14.26	[-24.55, -2.89]	0.02
		Total effect	-14.02	[-24.20, -3.61]	0.01
		Proportion Mediated	-1.7%	[-0.57, 0.53]	0.91
Fusicatenibacter	Congruent RT	Mediation effect	0.86	[0.79, 3.40]	0.30
		Direct effect	-14.65	[-25.75, -4.12]	0.01
		Total effect	-13.79	[-23.91, -3.76]	0.01
		Proportion Mediated	-6.2%	[-0.28, 0.08]	0.30
Acetate	Congruent RT	Mediation effect	-1.42	[-4.32, 0.78]	0.22
		Direct effect	-10.98	[-22.99, -2.36]	0.03
		Total effect	-12.39	[-24.27, -3.77]	0.01
		Proportion Mediated	11.4%	[-0.11, 0.54]	0.23
Propionate	Congruent RT	Mediation effect	-1.06	[-3.59, 0.96]	0.33
		Direct effect	-12.82	[-23.65, -2.58]	0.01
		Total effect	-13.88	[-24.2, -3.61]	0.01
		Proportion Mediated	7.6%	[-0.09, 0.38]	0.33

Mediation analysis, frequentist approach, was performed using nonparametric bootstrapped linear regression models with the mediation (v4.5.0) package to estimate the indirect (mediation), direct, and total effects of treatment on congruent reaction time (RT), with fecal *Parabacteroides*, *Fusicatenibacter*, acetate, and propionate as mediators (n = 37). Proportion mediated reflects the percent of the total effect explained by the indirect pathway.

Table 7. Moderation Effects of Fecal Microbiota and Metabolites on the Association

Between SCF and Congruent Reaction Time at end-point

Moderator	Flanker Task	Effect	Estimate	SE	[95% CI]	*P*
Parabacteroides	Congruent RT	Main effect	-0.35	3.78	[-7.91, 7.21]	0.08
		Moderation effect	0.29	3.26	[-6.22, 6.79]	**0.03***
Fusicatenibacter	Congruent RT	Main effect	-0.09	3.2	[-6.49, 6.31]	0.57
		Moderation effect	0.03	3.10	[-6.16, 6.23]	0.79
Acetate	Congruent RT	Main effect	-0.19	9.05	[-18.26, 17.89]	0.07
		Moderation effect	0.08	11.68	[-23.25, 23.41]	0.43
Propionate	Congruent RT	Main effect	-0.17	7.38	[-14.90, 14.56]	0.11
		Moderation effect	0.09	10.23	[-20.35, 20.52]	0.34

Moderation analysis was conducted using linear regression models including interaction terms between treatment and each moderator (n = 37). Models examined whether selected genera (CLR transformed) and metabolites modified the effect of treatment on congruent reaction time (RT). Reported values include standardized estimates (β), standard errors (SE), 95% confidence intervals (CI), and *P*-values.

Figure 1. CONSORT (Consolidated Standards of Reporting Trials) Flow Diagram of

Participant Recruitment, Randomization, and Retention in the Crossover Trial. Each "*n*"

reflects the number of participants at each stage of enrollment, randomization, and follow-up.

Following eligibility screening, participants were randomized to begin with either the

maltodextrin or soluble corn fiber condition in a counterbalanced crossover design. Participants

were retained in the study as long as they completed the primary outcome assessments, including

cognitive testing at each intervention timepoint.

Figure 2. The 16S relative abundance of genera for each subject across both timepoints and treatments. Stacked bar plots display the genus-level composition of the fecal microbiota for each participant across both treatment periods. Relative abundance (%) is expressed as the proportion of total sequences per sample from 16S sequences. Key genera are color-coded: *Parabacteroides* (orange), *Fusicatenibacter* (blue), *Dialister* (dark gray), and *Bacteroides* (gray). Each bar represents a single participant sample at a given timepoint.

Figure 3. Spearman Correlation Heatmap between Reaction Times and relevant variables following Soluble Corn Fiber Intervention. Heatmap illustrating Spearman correlation coefficients (ρ) among the relative abundance of selected genera identified in 16S differential abundance analysis, fecal SCFA concentrations, and reaction times from both Flanker trials (n = 37; SCF arm only). Positive correlations are shown in orange, negative correlations in blue, with shading intensity reflecting the magnitude of the correlation. Statistical significance is annotated as follows: *P < 0.05; †P < 0.1.

Figure 4. Moderation of the Treatment Effect on Congruent Reaction Time by Parabacteroides Abundance. Moderation model results illustrating the association between post-intervention Parabacteroides abundance (CLR-transformed, mean-centered) and the effect of treatment on congruent reaction time (RT) at endpoint (n = 37). Panel A) estimated marginal means and standard errors of estimated RT by treatment group at low (–1 SD), mean, and high (+1 SD) values of *Parabacteroides* abundance. Panel B) the estimated treatment effect (SCF – CON) on RT across the continuous range of *Parabacteroides* abundance, with 95% confidence intervals. The horizontal dashed line at zero represents no treatment effect. Estimates were derived from linear models described in the methods. Simple slopes and confidence intervals were generated using the Johnson-Neyman procedure, statistical significance is annotated as follows: ***$P < 0.001$.

Figure 5. Growth Dynamics of *Parabacteroides distasonis* Cultures in M9 Medium Supplemented with Individual Carbohydrates. Panel A) Relative log growth ($\ln[OD/OD_0]$) of *P. distasonis* over time in M9 minimal medium supplemented with different carbohydrate sources. OD_0 represents the initial optical density (OD_{600}) at time zero. Each curve represents a mean biological replicate (N = 3), and error bars indicate propagated standard deviations. Panel B) Mean growth rate (μ, hr^{-1}), calculated as the slope of $\ln(OD)$ over sequential 2-hour intervals.

Bars represent average growth rate across replicates. Significance levels: †P < 0.1, *P < 0.05, **P < 0.01, ***P < 0.001, NS = not significant.

Figure 6. Differential Abundance of Predicted Carbohydrate Metabolism KOs at Endpoint Between Treatment. PICRUSt2-predicted KEGG Orthologs (KOs) related to carbohydrate metabolism with positive MaAsLin2 coefficients at post-intervention (POST) are shown (N = 39). Each bar represents the effect size (coefficient) and standard error estimating the direction and magnitude of the association between soluble corn fiber (SCF) treatment and KO abundance relative to control. Positive coefficients indicate higher predicted abundance in the SCF group; larger absolute values reflect stronger associations.

Figure 7. Differential Abundance of Carbohydrate Metabolism-Associated Genes Between Responders and Non-Responders to Soluble Corn Fiber Intervention. Heatmap displaying the abundance of carbohydrate metabolism-related gene families annotated by HUMAnN 3.0 across six participants (N = 6), stratified by responder (R1–R3) and non-responder (NR1–NR3) status. Genes families shown (rows) were selected from a total of 1,180 unique carbohydrate-associated gene families based on a $\log_2$ fold change > 2 in mean abundance between responders and non-responders [log2(R/NR)]. The top 40 gene families are presented. Abundance values were row-scaled using Z-score normalization to emphasize relative variation across samples. Orange indicates higher abundance, and blue indicates lower abundance for each gene.

Figure 8. Species-Level Contributions to Carbohydrate Metabolism Gene Abundance Before and After Soluble Corn Fiber Intervention. Heatmaps showing the contribution of individual species (columns) to the abundance of 40 carbohydrate metabolism-associated gene families (rows) in six participants (N = 6). Panel A) before the SCF intervention, Panel B) after the SCF intervention. Gene abundance was row-normalized using Z-scores to highlight species-level contributions, with orange indicating higher and blue indicating lower abundance for each gene.